Tubal ligation and risk of ovarian cancer subtypes: A pooled analysis of case-control studies

International Journal of Epidemiology

Volumn 42, Issue 2, 2013, Pages 579-589

  Sieh, Weiva ^a   Salvador, Shannon ^b   McGuire, Valerie ^a   Weber, Rachel Palmieri ^c   Terry, Kathryn L ^d   Rossing, Mary Anne ^e   Risch, Harvey ^f   Wu, Anna H ^g   Webb, Penelope M ^h   Moysich, Kirsten ⁱ   Doherty, Jennifer A ^j   Felberg, Anna ^a   Miller, Dianne ^b   Jordan, Susan J ^h   Goodman, Marc T ^k   Lurie, Galina ^k   Chang Claude, Jenny ^l   Rudolph, Anja ^l   Kjær ̈ger, Susanne Kru ^m,n   Jensen, Allan ^m   Høgdall, Estrid ^m,n   Bandera, Elisa V ^o   Olson, Sara H ^p   King, Melony G ^o   Rodriguez Rodriguez, Lorna ^o   Kiemeney, Lambertus A ^q   Marees, Tamara ^q   Massuger, Leon F ^q   van Altena, Anne M ^q   Ness, Roberta B ^r   Cramer, Daniel W ^d   Pike, Malcolm C ^g,p   Pearce, Celeste Leigh ^g   Berchuck, Andrew ^c   Schildkraut, Joellen M ^c   Whittemore, Alice S ^a   more..

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f YALE UNIVERSITY   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j DARTMOUTH MEDICAL SCHOOL   (United States)

^k UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^l GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^m DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

ⁿ UNIVERSITY OF COPENHAGEN   (Denmark)

^o ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^q RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^r UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

Ovarian cancer; Tubal ligation; Tubal sterilization

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

AGE; CANCER; CONTRACEPTIVE USE; DATA ACQUISITION; HISTOLOGY; RISK; STERILIZATION;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK REDUCTION; UTERINE TUBE LIGATION;

EID: 84877085941     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyt042     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ (ed.). Blaustein's Pathology of the Female Genital Tract. 5th edn. New York: Springer, 2002.
3. Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009;16:267-82.
4. Vaughan S, Coward JI, Bast RC Jr et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11:719-25.
5. Köbel M, Kalloger SE, Boyd N et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
6. Lawrie TA, Nardin JM, Kulier R, Boulvain M. Techniques for the interruption of tubal patency for female sterilisation. Cochrane Database Syst Rev 2011 (2):CD003034.
7. Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 2011;17:55-67.
8. Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis. J Ovarian Res 2012;5:13.
9. Berchuck A, Schildkraut JM, Pearce CL, Chenevix-Trench G, Pharoah PD. Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium. Adv Exp Med Biol 2008;622:53-67.
10. Risch HA, Bale AE, Beck PA, Zheng W. PGR +331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2006;15:1738-41.
11. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2548-56.
12. Goodman MT, Lurie G, Thompson PJ, McDuffie KE, Carney ME. Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk. Endocr Relat Cancer 2008;15:1055-60.
13. Lurie G, Wilkens LR, Thompson PJ et al. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 2008;19:237-43.
14. Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB. Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol 2011;21:188-96.
15. Schildkraut JM, Iversen ES, Wilson MA et al. Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS One 2010;5: e10061.
16. Schildkraut JM, Moorman PG, Bland AE et al. Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev 2008;17:585-93.
17. Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 2005;65:5974-81.
18. Terry KL, Tworoger SS, Goode EL et al. MTHFR polymorphisms in relation to ovarian cancer risk. Gynecol Oncol 2010;119:319-24.
19. Bandera EV, King M, Chandran U, Paddock LE, Rodriguez-Rodriguez L, Olson SH. Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study. BMC Womens Health 2011;11:40.
20. Chandran U, Bandera EV, Williams-King MG et al. Healthy eating index and ovarian cancer risk. Cancer Causes Control 2011;22:563-71.
21. McGuire V, Felberg A, Mills M et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 2004;160:613-18.
22. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril 2004; 82:186-95.
23. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 2001;95:370-74.
24. Glud E, Kjaer SK, Thomsen BL et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 2004;164:2253-59.
25. Huusom LD, Frederiksen K, Hogdall EV et al. Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study. Cancer Causes Control 2006;17:821-29.
26. Soegaard M, Jensen A, Hogdall E et al. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 2007;16:1160-66.
27. Merritt MA, Green AC, Nagle CM, Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008;122:170-76.
28. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994;140:585-97.
29. Seiler JS. The evolution of tubal sterilization. Obstet Gynecol Surv 1984;39:177-84.
30. Westhoff C, Davis A. Tubal sterilization: focus on the U.S. experience. Fertil Steril 2000;73:913-22.
31. Gilks CB, Ionescu DN, Kalloger SE et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008;39: 1239-51.
32. Chilvers CE, Pike MC, Taylor CN, Hermon C, Crossley B, Smith SJ. General practitioner notes as a source of information for case-control studies in young women. UK National Case-Control Study Group. J Epidemiol Community Health 1994;48:92-97.
33. Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 2005;96:520-30.
34. Woodruff JD. The pathogenesis of ovarian neoplasia. Johns Hopkins Med J 1979;144:117-20.
35. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-21.
36. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1212-20.
37. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999; 91:1459-67.
38. Cramer DW, Titus-Ernstoff L, McKolanis JR et al. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1125-31.
39. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008;9:1191-97.
40. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-3.
41. Pearce CL, Templeman C, Rossing MA et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012;13:385-94.
42. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-43.
43. Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 1996;144:363-72.
44. Whittemore AS. Quantitative theories of oncogenesis. In: Klein G, Weinhouse S (eds). Advances in Cancer Research. New York: Academic Press, 1978.